Experience

Renasant Bio Launches With $54.5 Million Seed Financing

July 10, 2025

Cooley advised Renasant Bio, a preclinical venture-backed biotech company focused on developing therapies for rare genetic kidney diseases, on its launch with $54.5 million in seed funding.

Related contacts

Sara Semnani
Partner, Santa Monica
Rachel Robichaux
Associate, Palo Alto
Allison Peth
Associate, Palo Alto

Related Practices & Industries

SiteOne Therapeutics to Be Acquired by Eli Lilly for up to $1 Billion

May 28, 2025

Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.

Read more

Related contacts

Laura Berezin
Partner, Seattle
Sara Semnani
Partner, Santa Monica
Rowook Park
Partner, San Diego
Charity Williams
Partner, San Diego
Rena Kaminsky
Special Counsel, Palo Alto
Todd Gluth
Partner, San Diego
Lila Hope
Partner, Palo Alto
Noel Ripberger-Scheick
Associate, Palo Alto
Tucker Cochenour
Associate, Palo Alto
Kristin O'Hanlon
Special Counsel, San Francisco
David Fletcher
Partner, Washington, DC
Jamie Leigh
Partner, San Francisco
Carly Mitchell
Partner, Washington, DC
Jeremy Morrison
Partner, Washington, DC
Gerard O'Shea
Partner, New York
Marty Schenker
Senior Counsel , San Francisco
Andrew Epstein
Special Counsel, Seattle
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Selin Akkan
Associate, Palo Alto
Mari Dugas
Associate, Washington, DC
Virat Gupta
Associate, Washington, DC
Joseph J. Kim
Associate, Palo Alto
Eileen Leman
Associate, Los Angeles
Ehijele Olumese
Associate, Santa Monica
Joseph Perry
Associate, Reston
Hannah Rausch
Associate, New York
Melody Van Horn
Senior Paralegal, Palo Alto

Related Practices & Industries

SiteOne Therapeutics Announces $100 Million Series C

December 18, 2024

Cooley advised SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough and other conditions, on its $100 million Series C financing.

Read more

Related contacts

Laura Berezin
Partner, Seattle
Sara Semnani
Partner, Santa Monica
Noel Ripberger-Scheick
Associate, Palo Alto
Annie Froehlich
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Tracy Rubin
Partner, Palo Alto
John Sellers
Senior Counsel, Palo Alto
Denny Won
Partner, San Francisco
Kimberly Nguyen
Special Counsel, Reston
Kristin O'Hanlon
Special Counsel, San Francisco
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Michelle Liskanich
Associate, Santa Monica
Michael Gladstone
Associate, New York
Joseph J. Kim
Associate, Palo Alto
Sarah Oliai
Associate, Washington, DC
Ehijele Olumese
Associate, Santa Monica
Melody Van Horn
Senior Paralegal, Palo Alto
Katie Kissner
Quantitative Analyst, San Francisco

Related Practices & Industries

ArsenalBio Closes Oversubscribed $325 Million Series C

September 4, 2024

Cooley advised Arsenal Biosciences (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors, on the close of its oversubscribed $325 million Series C financing round.

Read more

Related contacts

Josh Seidenfeld
Partner, Palo Alto
Sara Semnani
Partner, Santa Monica
Megan Browdie
Partner, Washington, DC
Annie Froehlich
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Kevin King
Partner, Washington, DC
John Sellers
Senior Counsel, Palo Alto
Shannon MacMichael
Special Counsel, Washington, DC
Julia Gage
Associate, San Francisco
Emily Lee
Associate, Palo Alto
Megan Stallworth
Associate, Palo Alto
Rubin Waranch
Associate, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York

Related Practices & Industries

Kyverna Therapeutics Closes $85 Million Series B

January 28, 2022

Cooley advised Kyverna Therapeutics on its $85 million Series B financing. Partners Laura Berezin and Sara Semnani led the Cooley team advising Kyverna, a developer of new cell-based therapeutics designed to offer treatments and cures for serious autoimmune and inflammatory diseases.

Related contacts

Laura Berezin
Partner, Seattle
Sara Semnani
Partner, Santa Monica
Han Wang
Associate, Santa Monica
Amy Lauren Saldamando
Manager of Capitalization Table Administration, Santa Monica

Related Practices & Industries

View more

Admissions and credentials

California